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Authors' reply
Sir, Thanks for raising some very important questions and issues regarding my article. [1, 2] The article was not a review article to cover the entire gamut of management of vernal keratoconjunctivitis. Nonpharmacologic therapy and surgical management were not the main focus. The article was written to present a simple grading system and medical management scheme based on this grading system. The objective was to give a new insight onto how we could better treat severe allergies in our clinics.
Nonpharmacologic management was outside the purview and can be a separate article by itself. It includes allergen avoidance, protective goggles, hygiene, mite and mold control, air filtration systems, allergy testing and desensitization, and multiple environmental control interventions. Not rubbing the eyes, cold compresses, face washing, washing hands, etc., are indeed important factors as you have mentioned and are well known to most ophthalmologists.
The preservative-free lubricants are very helpful and always used in severe allergy; however, I am not aware of how they can reduce the risk of hypersensitivity to other preservatives used by the patients.
Loteprednol has been my preferred topical steroid because of its greater safety and lower potency to cause cataract and glaucoma. However, one could use fluorometholone, dexamethasone, and prednisolone eye drops in more severe cases if desired.
The low, long-term safety profile of traditional corticosteroids led to the development of modified corticosteroids such as loteprednol that retain the anti-inflammatory mechanism of action of traditional corticosteroids with a much-improved safety profile, because of their rapid breakdown to inactive metabolites after exerting their activity. Loteprednol etabonate has an ester (instead of a ketone) group at the carbon-20 (C-20) position of the basic corticosteroid structure. Clinical trials assessing this C-20 ester corticosteroid have revealed similar efficacy to C-20 ketone corticosteroids in the prevention or treatment of the signs and symptoms of seasonal allergic conjunctivitis, but with a greatly improved safety profile, as the C-20 ester corticosteroid is less likely to elevate intraocular pressure. In addition, the ketone at the C-20 position has been implicated in the formation of cataract while nonketolic corticosteroids do not form Schiff base intermediates with lens proteins, which is a common first step in cataractogenesis. Loteprednol etabonate offers a well-tolerated treatment option for patients with debilitating acute exacerbations as well as chronic forms of the disease. [3] Long-term data for more than 12 months are now available for use of loteprednol in allergic conjunctivitis. [4] In another study, lotepredenol was as effective as prednisolone and more effective than fluorometholone, and it had no side effects during the short-term treatment of vernal keratoconjunctivitis patients. [5] Loteprednol has a lower propensity to cause intraocular pressure rise in steroid responders as compared to prednisolone. [6] On the other hand, 60.5% of steroid responder patients showed a rise in intraocular pressure of more than 5 mm Hg even after the use of fluorometholone. [7] A word of caution with regard to fluorometholone use in children is because of its higher propensity to cause a steroid response, especially when used at a higher frequency or for a longer period. [8] In severe allergies, we would still try allergen avoidance, lubricants, antihistaminics, and mast cell stabilizers because they would reduce the dosage needed for more potent immunosuppressive medications. A multipronged approach has to be used in these patients.
For severe cases, we need to start with multiple medications in the acute stage and then based on response to therapy further modify therapy. If there is a better algorithm that comes up in the future, I would be happy to put it into my practice.
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Comment on: An unusual presentation of nonarteritic ischemic optic neuropathy with subretinal fluid treated with intravitreal bevacizumab
Sir, It was with great interest we read the article "An unusual presentation of nonarteritic ischemic optic neuropathy (NAION) with subretinal fluid treated with intravitreal bevacizumab" by Dave and Pappuru. [1] We have noticed some points in the text and would like to put forth few queries which we feel were not addressed adequately in this article.
Diabetic status of the patient has not been mentioned. It is known that diabetes mellitus, apart from hypertension, is a predisposing factor for the development of NAION and the characteristics of such patients differ from nondiabetic patients with NAION. [2] We agree that macular edema is an unusual finding in NAION even in fundus fluorescein angiography (FFA) studies as mentioned by the authors. Yet the authors have not mentioned FFA findings in the article. We believe FFA of the affected eye is essential in cases of atypical NAION with sub retinal fluid (SRF) to rule out inflammatory pathologies. Other eye's visual fields, fundus image, FFA, and optical coherence tomography would have been helpful for comparison and to rule out any other pathologies. Improvement in visual acuity cannot be contributed to intravitreal bevacizumab with certainty as vision is known to improve, in >40% cases, with the natural history of disease. [3] Authors have documented 20/200 best-corrected visual acuity in other eye post-NAION. Hayreh and Zimmerman have shown the difference in final visual outcomes in eyes of patients with bilateral sequential NAION. [4] Low final vision in one eye cannot be used as a predictor of poor prognosis when other eye develops NAION and should not be an indication for interventional treatment.
Authors have documented an improvement in visual acuity but have not commented on the visual fields during follow-up.
We found two reports of intravitreal bevacizumab being associated with the development of NAION in literature and we are mentioning one due to the restriction of a number of references. [5] It is postulated to be due to the transient raised IOP caused by the injection affecting the already compromised optic disc. Keeping this in mind and the fact that NAION recovers to some extent in its natural history, we feel that this therapy needs to be proved through proper randomized trials before being tried in NAION patients.
Macular edema and subretinal fluid have also been described in literature and have been shown to resolve without use of any treatment. [2] We feel the presence of subretinal fluid or macular edema does not necessitate treatment in such cases.
The authors, Dave et al. have mentioned in their reference number 11 that the article on "Macular star in Optic neuropathy" by Wang AG, Lui JH, Lin CL, and Yen MY was published in "Am J Ophthalmol," when in fact it was published in "Annals of ophthalmology" in 1995.
The abstract mentions the last follow-up being at 6 months while text documents it as 3 months.
